Genetic effect of type 2 Diabetes to the progression of Neurological Diseases

Md Habibur Rahman^{1,2,3}, Silong Peng^{1,2,4}, Chen Chen¹, Pietro Lio⁵, Mohammad Ali Moni^{6,*}

¹Institute of Automation, Chinese Academy of Sciences, Beijing 100190, China.

²University of Chinese Academy of Sciences, Beijing 100190, China.

³Dept. of Computer Science and Engineering, Islamic University, Kushtia-7003, Bangladesh.

⁴Beijing Visytem Co. Ltd.

⁵Computer Laboratory, The University of Cambridge, UK.

⁶Faculty of Medicine and Health, The University of Sydney, Australia.

Email of the Corresponding author: mohammad.moni@sydney.edu.au

Abstract

Neurological Diseases (NDs) are progressive disorder often advances with age and comorbidities of Type 2 diabetes (T2D). Epidemiological, clinical and neuropathological evidence advocate that patients with T2D are at an increased risk of getting NDs. However, it is very little known how T2D affects the risk and severity of NDs.

To tackle these problems, we employed a transcriptional analysis of affected tissues using agnostic approaches to identify overlapping cellular functions. In this study, we examined gene expression microarray human datasets along with control and disease-affected individuals. Differentially expressed genes (DEG) were identified for both T2D and NDs that includes Alzheimer Disease (AD), Parkinson Disease (PD), Amyotrophic Lateral Sclerosis (ALS), Epilepsy Disease (ED), Huntington Disease (HD), Cerebral Palsy (CP) and Multiple Sclerosis Disease (MSD).

We have developed genetic association and diseasome network of T2D and NDs based on the neighborhood-based benchmarking and multilayer network topology approaches. Overlapping DEG sets go through protein-protein interaction for hub protein identification and gene enrichment using pathway analysis and gene ontology methods that enhance our understanding of the fundamental molecular procedure of NDs progression.

Gene expression analysis platforms have been extensively used to investigate altered pathways and to identify potential biomarkers and drug targets. Finally, we validated our identified biomarkers using the gold benchmark datasets which identified the corresponding relationship of T2D and NDs. Therapeutic targets aimed at attenuating identified altered pathway could ameliorate neurological dysfunction in a T2D patient.

Keywords-Type 2 diabetes, Neurological Diseases, hub protein, pathway, ontology, therapeutic targets.

I. Introduction

Diabetes mellitus(DM) derived from Greek word *Diabetes* stands *to pass through* and *Mellitus* is a Latin word for *honey*[1], often simply referred to as diabetes was firstly reported in Egyptian manuscript about 3000 years ago[2] and clearly made a distinction between type1 and type2 DM in 1936[3]. Type 2 Diabetes(**T2D**) mellitus first described as a component of metabolic syndrome in 1988[4] is the most common form of DM characterized by hyperglycemia, insulin resistance, and relative insulin deficiency. The global rise in type 2 diabetes (T2D) incidence estimating 439 million people by the year 2030[5] is known to be a nonreversible clinical issue with the attendant chronic kidney disease, amputation, blindness, various cardiac and vascular disease issues such as *strokes, heart disease, retinopathy, and peripheral ischemia. Its high incidence rate raises* issues of its interaction with other diseases occurring (or at risk of occurring) in the same individuals,i.e,co-morbidities. Epidemiological, clinical and neuropathological evidence advocate that patients with type 2 diabetes are at an increased risk of getting Neurological Diseases(NDs)[6,7,8].Neurological diseases(NDs) are characterized by selective dysfunction and loss of neurons associated with pathologically altered proteins that deposit in the human brain but also in peripheral organs[7,9]. NDs primarily attack the neurons of the central nervous system and progressively damage the function of them. Neurons are most vulnerable to injury and normally don't reproduce or replace themselves [10]. If neurons become damaged or die they cannot be replaced by medical treatments. So that NDs are very dangerous and currently they don't have any cure. We studied several NDs Include Alzheimer Disease (AD), Parkinson Diseases (PD), Amyotrophic Lateral Sclerosis (ALS), Epilepsy Diseases(ED), Huntington Diseases (HD), Cerebral Palsy (CP) and Multiple Sclerosis Diseases (MSD) to find the effects of T2D on them. Alzheimer Disease (AD), the most common type of incurable dementia is characterized by progressive neuronal loss, cognitive deterioration, and behavioral changes. Accumulation of amyloid or senile plaques and formation of neurofibrillary tangles are thought to be the major cause of neuronal loss in the AD brain[11,12]. PD is featured by progressive death of dopaminergic neurons in the substantia nigra and characterized by clinical symptoms including progressive impairment of movement control, cognitive decline, depression, anxiety, and olfactory dysfunction. Insulin dysregulation and changes in insulin action are concerned with developing Parkinson's disease [11,13].LGD also cognizant as Amyotrophic lateral sclerosis (ALS), is one of the major neurological diseases alongside Alzheimer's disease and Parkinson's disease that progressively damages motor neurons and muscle atrophy controlling voluntary muscle movement. Muscle weakness or stiffness is the initial symptoms of ALS. ALS patients are hypermetabolic and have impaired glucose tolerance associated with T2D[14].ED is a heterogeneous group of neurodegenerative disorder that affects neural cells in the brain which are recognized by recurrent seizures or unusual behavior, awareness and sensations and high levels of β -amyloid in the brain can cause epileptiform activity[15].HD is an inherited disorder

characterized by the selective loss of medium spiny neurons from the striatum, leading to neuropsychiatric changes and movement disorder and the molecular cause of HD is the expansion of a CAG trinucleotide repeat in the gene encoding huntingtin(HTT), resulting in a polyglutamine stretch in the N-terminus of the protein[16]. Cerebral Palsy (CP) is a well-known group of disorders of movement, muscle tone, or other features that reflect abnormal control over motor function by the central nervous system[17]. Multiple sclerosis disease(MSD) is a chronic inflammatory and demyelinating disease of the central nervous system, which causes neurological disability due to the selective autoimmune destruction of white matter, ultimately leading to axonal loss. Genetic and environmental factors are thought to contribute to the pathogenesis of this disease[18][19].

How these are influenced by T2D is poorly understood, and typically studied by classical endocrinology approaches that focus on the effects of T2D associated cell secretions and serum glucose and glycation product levels. Although discoveries are continuing to be made in this field, the main causes or risk factors of NDs remain poorly understood.

To address these issues, here, we have proposed a novel computation-based approach, seeking to identify gene expression pathways common to T2D and NDs, as gene expression is profoundly affected by the disease processes themselves as well as predisposing genetic and environmental factors. Our approach aims to find overlapping pathways of potential clinical utility, but may also identify important new pathways relevance to many diseases.

With global transcriptome analyses, we investigated in detail common gene expression profiles of T2D and AD, PD, ALS, ED, HD, CP, and MSD. To understand the genetic effects of T2D on NDs, we examined gene expression dysregulation, disease association network, dysregulated pathway, gene expression ontology, and protein-protein interaction along with hub protein identification. We also investigated the validation of our study by using the gold benchmark databases (dbGAP and OMIM). This network-based approach identified significant common pathways influencing these diseases.

II. MATERIALS AND METHODS

A. Overview of analytical approach

A systematic and quantitative approach to evaluate human disease comorbidities using different sources of gene expression microarray data is summarized as shown in Fig. 1. This approach employs gene expression analyses, disease gene associations network, signaling pathway mechanism, Gene Ontology (GO) data, and protein-protein interaction network to identify putative components of common pathways between T2D and Neurological diseases (NDs).

B. Datasets employed in this study

To investigate the molecular pathways involved in T2D on AD, PD, ALS, ED, HD, CP, and MSD at the molecular level, we first analyzed gene expression microarray datasets. In this study, we

collected raw data from the Gene Expression Omnibus of the National Center for Biotechnology Information (NCBI) (<http://www.ncbi.nlm.nih.gov/geo/>).

Fig. 1: overview of the network-based approach.

We analyzed 8 different large human gene expression datasets having control and disease affected individuals for our study with accession numbers GSE23343[20], GSE28146[21], GSE19587[22], GSE833[23], GSE22779[24], GSE1751[25], GSE31243[26] , and GSE38010[27]. The T2D dataset (GSE23343) contains gene expression data obtained through extensive analysis after conducting liver biopsies in the human. The AD dataset (GSE28146) is a microarray data on RNA from fresh frozen hippocampal tissue blocks that contain both white and gray matter, potentially obscuring region-specific changes. The PD dataset (GSE19587) is taken from 6 postmortem brains of PD patients and from 5 control brains. The LGD dataset (GSE833) is an Affymetrix Human Full Length HuGeneFL [Hu6800] Array. In this data, postmortem spinal cord grey matter from sporadic and familial ALGD patients are compared with controls. The ED dataset (GSE22779) is a gene expression profiles of 4 non-leukemic individuals (1 healthy and 3 with epilepsy) is generated from the mononuclear cells isolated from the peripheral blood samples before, and after 2, 6, and 24 hours of in-vivo glucocorticoid treatment. The CP (GSE31243) is an Affymetrix human genome U133A 2.0 array where 40 microarrays are provided into four groups to analyze the effect of cerebral palsy and differences between muscles. The Huntington Disease(HD) dataset(GSE1751) is an Affymetrix U133A expression levels for 12 symptomatic and 5 presymptomatic Huntington's disease patients with 14 healthy controls. The MSD dataset (GSE38010) is a microarray data of multiple sclerosis (MS) patients brain lesions compared with control brain samples.

C. Analysis methods

Analyzing oligonucleotide microarray data for gene expression is known to be an effective and responsive approach to demonstrate the molecular assessors of human diseases. Using DNA

microarrays technologies with global transcriptome analyses, we compared the gene expression profiles of T2D with that in our AD, PD, ALS, ED, HD, CP, and MSD datasets to find the effect of T2D on them. All these datasets were generated by comparing diseased tissue with normal to identify differentially expressed genes (DEG) associated with their respective pathology. To uniform the mRNA expression data of different platforms and to avoid the problems of experimental systems, we normalized the gene expression data (disease state or control data) by using the Z-score transformation (Z_{ij}) for each NDs gene expression profile using the following equation:

$$Z_{ij} = \frac{g_{ij} - \bar{g}}{\sigma_i} \quad (1)$$

Where σ_i implies the standard deviation, g_{ij} represents the value of the gene expression i in sample j . These datasets were obtained and detected DEGs with their respective pathology to compare disease tissue with a normal one. We used $\log_2$ transformation and calculated expression level of each gene implementing linear regression: $Y_i = a_0 + a_1 X_i$ where X_i is a disease state(case and control), a_0 and a_1 are considered the coefficient of this model estimating with least squares and Y_i is the gene expression value. Student's unpaired t-test was employed between two conditions and performed to find out DEGs over normal samples in patients and significant genes were preferred. A threshold of at least 1 log2 fold change and a p-value for the t-tests of $\leq 5 * 10^{-2}$ were chosen. In addition, a two-way ANOVA with Bonferroni's post hoc test was used to determine statistical significance between groups (<0.1). Gene symbol and title of different genes are extracted from each disease. Null gene symbol records are discarded from each disease. We also find out unique genes both over and under-expression genes. The most important up and down-regulated genes are selected between individual disease and T2D.

There are applied neighborhood benchmarking and topological methods to show the associations between genes and diseases. A gene-disease network was built(GDN) regarding the connection of gene-disease where nodes can be either diseases or genes such a network can be represented as a bipartite graph whether T2D is the center of this network using Cytoscape V 3.6.1[28]. Diseases are associated when they share at least one significant dysregulated gene. Given a particular set of human diseases D and a set of human genes G , gene-disease associations attempt to find whether gene $g \in G$ is associated with diseases $d \in D$. If G_i and G_j , the sets of significant up and down-dysregulated genes associated with diseases D_i and D_j respectively, then the number of shared dysregulated genes (n_{ij}^g) associated with both disease D_i and D_j is as follows[29]:

$$n_{ij}^g = N(G_i \cap G_j) \quad (2)$$

Co-occurrence refers to the number of shared genes in the GDN and common neighbors identified employing the Jaccard Coefficient method, where the edge prediction score for the node pair is:

$$E(i,j) = \frac{N(G_i \cap G_j)}{N(G_i \cup G_j)} \quad (3)$$

Where G is the set of nodes and E is the set of all edges. We used R software packages “comoR”[30] and “POGO”[31] to cross check the disease comorbidity associations.

To get further insight into the molecular pathways of T2D that overlap with the AD, PD, ALS, ED, HD, CP, and MSD, we performed pathway and gene ontology analysis using the Enrichr[32], and KEGG pathways database [33]. We also generated a protein-protein interaction (PPI) network for each disease pair datasets, using data from the STRING database [stringdb.org] where proteins are represented by nodes and the interaction between two proteins are represented by edges. Furthermore, we also incorporated three gold benchmark verified datasets, OMIM (www.omim.org), OMIM Expanded, and dbGaP (www.ncbi.nlm.nih.gov/gap) for retrieving the genes of all known diseases, relevant disorders, and genotype-phenotype relationships, in our study for validating the proof of principle of our network-based approach.

III. RESULTS

A. Gene Expression Analysis

To investigate the effects of T2D on NDs, we analyzed the gene expressing microarray data from the National Center for Biotechnology Information (NCBI) (<http://www.ncbi.nlm.nih.gov/geo/>). We found that 1320 genes were differentially expressed for T2D with False Discovery Rate(FDR) below 0.05 $|\log FC| \geq 1$ using R Bioconductor packages(Limma) . Among them, 622 and 698 were up and down-regulated respectively. Similarly, our analysis identified the most significant differentially expressed genes for each NDGD after various steps of statistical analysis. We identified differentially expressed genes, 1606 (847 up and 759 down) in AD, 1588 (1167 up and 422 down) in PD, 2901 (735 up and 2166 down) in ALS, 1887 (882 up and 1007 down) in ED , 1338 (365 up and 973 down) in HD , 588 (243 up and 345 down) in CP and 7463 (3987 up and 3476 down) in MSD. The cross-comparative analysis was also performed to find the common differentially expressed genes between T2D and each ND. We observed that T2D shares 3,21,4,13,7,11 and 35 significantly up-regulated genes and 12,2,25,16,6,5 and 28 significant down-regulated genes with AD,PD,ALS,ED,HD,CP and MSD respectively. To find statistically significant associations among these diseases, we built up and down diseasome relationships network centered on the T2D as shown in fig. 2A and 2B in which two diseases are comorbid if there exist one or more genes that are associated with both diseases [34].Notably, 5 significant genes FLI1, PACSIN2, BICD1, TCP11L2, and ENTPD1 are commonly up-regulated among T2D, ED, and MSD. While 2 significant genes PEG10 and EFCAB14 are up-regulated among T2D, PD, and MSD. ITGB8 is up-regulated among T2D, HD, PD, and MSD.FBLN1 is up-regulated among T2D, ALS, and MSD.IGFBP5 is up-regulated among T2D, CP, and MSD.SGCB is up-regulated among T2D, HD, and MSD.SLC25A30 is up-regulated among T2D, PD, and CP. On the other hand,

A. Common significant pathways of T2D and AD

KEGG ID	Term	Genes in the pathway	Adjusted P-value
hsa00604	Glycosphingolipid biosynthesis- ganglio series	ST6GALNAC5	1.12E-02
hsa00601	Glycosphingolipid biosynthesis - lacto anneolacto series	FUT6	1.93E-02
hsa05310	Asthma_Homo sapiens	HLA-DQB1	2.30E-02
hsa05330	Allograft rejection	HLA-DQB1	2.81E-02
hsa05332	Graft-versus-host disease	HLA-DQB1	3.03E-02
hsa04672	Type I diabetes mellitus	HLA-DQB1	3.18E-02
hsa04940	Intestinal immune network for IgA production	HLA-DQB1	3.54E-02
hsa05320	Autoimmune thyroid disease	HLA-DQB1	3.90E-02
hsa05150	Staphylococcus aureus infection	HLA-DQB1	4.12E-02
hsa05416	Viral myocarditis	HLA-DQB1	4.34E-02
hsa04721	Synaptic vesicle cycle	RIMS1	4.62E-02
hsa05321	Inflammatory bowel disease (IBD)	HLA-DQB1	4.77E-02

B. Common significant pathways of T2D and PD

KEGG ID	Pathway	Genes in the pathway	Adjusted P-value
hsa04514	Cell adhesion molecules (CAMs)	CD86;ITGB8	1.15E-02
hsa04810	Regulation of actin cytoskeleton	MYH14;ITGB8	2.49E-02
hsa00512	Mucin type O-Glycan biosynthesis	GALNT12	3.51E-02
hsa05330	Allograft rejection	CD86	4.28E-02
hsa05332	Graft-versus-host disease	CD86	4.61E-02
hsa04940	Type I diabetes mellitus	CD86	4.83E-02

C. Common significant pathways of T2D and ALS

KEGG ID	Pathway	Genes in the pathway	Adjusted P-value
hsa00601	Glycosphingolipid biosynthesis- lacto and neolacto series	FUT6	3.70E-02
hsa00061	Fatty acid biosynthesis	OLAH	1.87E-02

D. Common significant pathways of T2D and ED

KEGG ID	pathway	Genes in the pathway	Adjusted P-value
hsa04110	Cell cycle	E2F5;CDC14B	1.39E-02
hsa00230	Purine metabolism	ENTPD1;ADK	2.68E-02

E. Common significant pathways of T2D and HD

KEGG ID	Pathway	Genes in the pathway	Adjusted P-value
hsa05412	Arrhythmogenic right ventricular cardiomyopathy (ARVC)	SGCB;ITGB8	1.03E-03
hsa04512	ECM-receptor interaction	ITGB8;CD47	1.26E-03
hsa05410	Hypertrophic cardiomyopathy (HCM)	SGCB;ITGB8	1.29E-03
hsa05414	Dilated cardiomyopathy	SGCB;ITGB8	1.51E-03
hsa00601	Glycosphingolipid biosynthesis - lacto and neolacto series	GCNT2	1.68E-02
hsa05033	Nicotine addiction	GRIN1	2.57E-02
hsa05030	Cocaine addiction	GRIN1	3.14E-02
hsa00510	N-Glycan biosynthesis	ALG13	3.14E-02
hsa05014	Amyotrophic lateral sclerosis (ALS)	GRIN1	3.27E-02
hsa05416	Viral myocarditis	SGCB	3.77E-02
hsa04720	Long-term potentiation	GRIN1	4.21E-02
hsa05031	Amphetamine addiction	GRIN1	4.27E-02

F.Common significant pathways of T2D and CP

KEGG ID	Pathway	Genes in the pathway	Adjusted P-value
hsa05032	Morphine addiction	PDE4D;PDE3A	2.36E-03
hsa00230	Purine metabolism	PDE4D;PDE3A	8.52E-03
hsa04024	cAMP signaling pathway	PDE4D;PDE3A	1.08E-02
hsa04144	Endocytosis	ACAP2;DNM1	1.78E-02
hsa00760	Nicotinate and nicotinamide metabolism	NADSYN1	2.30E-02
hsa04961	Endocrine and other factor-regulated calcium reabsorption	DNM1	3.70E-02
hsa04721	Synaptic vesicle cycle	DNM1	4.92E-02

G.Common significant pathways of T2D and MSD

KEGG ID	Pathway	Genes in the pathway	Adjusted P-value
hsa04721	Synaptic vesicle cycle	RIMS1;DNM1;DNM2	1.03E-03
hsa04961	Endocrine and other factor-regulated calcium reabsorption	DNM1;DNM2	9.64E-03
hsa04072	Phospholipase D signaling pathway	DGKE;DNM1;DNM2	1.06E-02
hsa05412	Arrhythmogenic right ventricular cardiomyopathy (ARVC)	SGCB;ITGB8	2.28E-02
hsa05100	Bacterial invasion of epithelial cells	DNM1;DNM2	2.52E-02
hsa05410	Hypertrophic cardiomyopathy(HCM)	SGCB;ITGB8	2.82E-02
hsa05414	Dilated cardiomyopathy	SGCB;ITGB8	3.28E-02
hsa05231	Choline metabolism in cancer	DGKE;SP1	4.04E-02
hsa04723	Retrograde endocannabinoid signaling	GRIA2;RIMS1	4.04E-02
hsa00604	Glycosphingolipid biosynthesis - ganglio series	ST6GALNAC5	4.62E-02

C. Gene Ontology Analysis

The Gene Ontology (GO) refers to a universal conceptual model for representing gene functions and their relationship in the domain of gene regulation. It is constantly expanded by accumulating the biological knowledge to cover regulation of gene functions and the relationship of these functions in terms of ontology classes and semantic relations between classes [36].To get further insight into the identified pathways, enriched common gene sets were processed by gene ontology methods using Enrichr which identifies related biological processes and groups them into functional categories. The list of processes was also curated for those with known involvement with the diseases of interest. The cell processes and genes identified are summarized on Table II.We observe that 10,20,29,18,14,24, and 30 significant ontological pathways, associated pathway genes and adjusted P-values are identified by Enrichr which are significantly connected with DEGs of T2D(See table A, B, C, D, E, F, and G). Moreover,we observed a number of the significant pathways that notably includes regulation of neurotransmitter transport (GO:0051588) and regulation of neurotransmitter secretion (GO:0046928) between AD and MSD, negative regulation of nervous system development (GO:0051961) between ALS and AD, negative regulation of signal transduction (GO:0009968) between ALS and CP, central nervous system neuron differentiation (GO:0021953) between ALS and ED, positive regulation of cellular process (GO:0048522), neural fate commitment (GO:0048663) and neural fate specification (GO:0048665) between ALS and HD, regulation of ERK1 and ERK2 cascade (GO:0070372) among

ALS, HD, and CP, neural crest cell differentiation (GO:0014033) among ALS, HD, and MSD, regulation of cell motility (GO:2000145) between ALS and MSD, neuronal action potential (GO:0019228) between ALS and PD, neurotransmitter receptor internalization (GO:0099590) between CP and MSD, protein localization to organelle (GO:0033365) between ED and MSD, mitotic spindle elongation (GO:0000022) between ED and PD, transmembrane receptor protein tyrosine kinase signaling pathway (GO:0007169) between HD and CP and finally extracellular matrix organization (GO:0030198) between HD and PD were observed.

Table II: Gene ontology identification of biological processes common to T2D and NDs.

A. Common significant GOs of T2D and AD

GO ID	Pathway	Genes in the pathway	Adjusted P-value
GO:0032000	positive regulation of fatty acid beta-oxidation	PLIN5	5.99E-03
GO:0016064	immunoglobulin mediated immune response	HLA-DQB1	6.73E-03
GO:2000269	regulation of fibroblast apoptotic process	STK17B	6.73E-03
GO:0031998	regulation of fatty acid beta-oxidation	PLIN5	8.22E-03
GO:0051588	regulation of neurotransmitter transport	RIMS1	1.05E-02
GO:0007498	mesoderm development	GDF11	1.64E-02
GO:0051961	negative regulation of nervous system development	ARHGEF15	1.71E-02
GO:0046928	regulation of neurotransmitter secretion	RIMS1	2.08E-02
GO:0043603	cellular amide metabolic process	FUT6	4.62E-02
GO:0009311	oligosaccharide metabolic process	ST6GALNAC5	4.70E-02

B. Common significant GOs of T2D and PD

GO ID	Pathway	Genes in the pathway	P-value
GO:0070486	leukocyte aggregation	S100A8	9.16E-03
GO:0070584	mitochondrion morphogenesis	MYH14	1.14E-02
GO:0090128	regulation of synapse maturation	ADGRL1	1.26E-02
GO:0045624	positive regulation of T-helper cell differentiation	CD86	1.37E-02
GO:0000022	mitotic spindle elongation	CDC14A	1.37E-02
GO:1900003	regulation of serine-type endopeptidase activity	CR1	1.37E-02
GO:0032990	cell part morphogenesis	MYH14	1.37E-02
GO:0048854	brain morphogenesis	SHANK2	1.37E-02
GO:0006939	smooth muscle contraction	SMTN	1.71E-02
GO:0003009	skeletal muscle contraction	MYH14	2.16E-02
GO:0043401	steroid hormone mediated signaling pathway	NR6A1	2.39E-02
GO:0019228	neuronal action potential	MYH14	2.73E-02
GO:0097061	dendritic spine organization	SHANK2	2.84E-02
GO:0030198	extracellular matrix organization	DPT;ITGB8	2.84E-02
GO:0030199	collagen fibril organization	DPT	3.40E-02
GO:0061448	connective tissue development	ITGB8	3.51E-02

GO:0048813	dendrite morphogenesis	SHANK2	3.73E-02
GO:0009312	oligosaccharide biosynthetic process	GALNT12	3.84E-02
GO:0099601	regulation of neurotransmitter receptor activity	SHANK2	3.84E-02
GO:1901606	alpha-amino acid catabolic process	MCCC2	4.50E-02

C.Common significant GOs of T2D and ALS

GO ID	Pathway	Genes in the pathway	Adjusted P-value
GO:0043496	regulation of protein homodimerization activity	NRG1;ISL1	2.72E-04
GO:0072091	regulation of stem cell proliferation	SIX3;FBLN1	2.72E-04
GO:0045892	negative regulation of transcription, DNA-templated	NR6A1;SIX3;NRG1;NR2F2;ZBTB7A;ISL1	9.49E-04
GO:1902117	positive regulation of organelle assembly	PLK4;CROCC	2.20E-03
GO:0006352	DNA-templated transcription, initiation	NR6A1;BRF1;TAF13	2.46E-03
GO:0050870	positive regulation of T cell activation	TFRC;CD47	4.48E-03
GO:2000113	negative regulation of cellular macromolecule biosynthetic process	SIX3; NRG1; NR2F2; ZBTB7A	6.11E-03
GO:0048935	peripheral nervous system neuron development	ISL1	1.01E-02
GO:0021522	spinal cord motor neuron differentiation	ISL1	1.01E-02
GO:0021559	trigeminal nerve development	ISL1	1.01E-02
GO:2000145	regulation of cell motility	NRG1;FBLN1	1.10E-02
GO:0048665	neuron fate specification	ISL1	1.15E-02
GO:0051094	positive regulation of developmental process	TFRC;ISL1	1.18E-02
GO:1902692	regulation of neuroblast proliferation	SIX3	1.58E-02
GO:0048663	neuron fate commitment	ISL1	2.01E-02
GO:2000177	regulation of neural precursor cell proliferation	SIX3	2.15E-02
GO:0014033	neural crest cell differentiation	NRG1	2.30E-02
GO:0008284	positive regulation of cell proliferation	NRG1;CD47;CYR61	2.31E-02
GO:0006355	regulation of transcription, DNA-templated	NR6A1;TAF13;SIX3;NRG1;NR2F2;ZBTB7A	2.49E-02
GO:1901990	regulation of mitotic cell cycle phase transition	PLK4;CDC14B	2.93E-02
GO:0045597	positive regulation of cell differentiation	ISL1;CYR61	3.23E-02
GO:0051961	negative regulation of nervous system development	GPR161	3.28E-02
GO:0019228	neuronal action potential	CACNA1H	3.42E-02
GO:0048522	positive regulation of cellular process	NRG1;CD47;ISL1	3.87E-02
GO:0021953	central nervous system neuron differentiation	ISL1	4.68E-02
GO:0000122	negative regulation of transcription from RNA polymerase II promoter	NR6A1; NR2F2; ISL1	4.78E-02
GO:0120031	plasma membrane bounded cell projection assembly	FGD6;CDC14B	4.78E-02
GO:0050768	negative regulation of neurogenesis	SIX3	4.82E-02
GO:0070372	regulation of ERK1 and ERK2 cascade	FBLN1; CYR61	4.99E-02

D.Common significant GOs of T2D and ED

GO ID	Pathway	Genes in the pathway	Adjusted P-value
GO:0006897	endocytosis	PACSIN2;RIN3;IGHA1	6.45E-03
GO:0033365	protein localization to organelle	PACSIN2;BICD1	8.85E-03
GO:0051251	positive regulation of lymphocyte activation	CD47;IGHA1	1.01E-02
GO:0007599	hemostasis	FLI1	1.15E-02
GO:0015822	ornithine transport	SLC25A29	1.15E-02
GO:0090286	cytoskeletal anchoring at nuclear membrane	SYNE2	1.30E-02
GO:0034214	protein hexamerization	YME1L1	1.44E-02
GO:0007010	cytoskeleton organization	PACSIN2;SYNE2	1.45E-02
GO:0034063	stress granule assembly	BICD1	1.73E-02
GO:0000022	mitotic spindle elongation	CDC14B	1.73E-02
GO:0097205	renal filtration	IGHA1	1.73E-02
GO:0035278	miRNA mediated inhibition of translation	TNRC6A	1.73E-02
GO:0071470	cellular response to osmotic stress	SERPINB6	2.15E-02
GO:0034656	nucleobase-containing small molecule catabolic process	ENTPD1	2.30E-02
GO:0009069	serine family amino acid metabolic process	SRR	2.58E-02
GO:0043949	regulation of cAMP-mediated signaling	UBE2B	2.72E-02
GO:0072522	purine-containing compound biosynthetic process	ADK	3.28E-02
GO:0021953	central nervous system neuron differentiation	DRAXIN	4.68E-02

E.Common significant GOs of T2D and HD

GO ID	Pathway	Genes in the pathway	Adjusted P-value
GO:0042127	regulation of cell proliferation	GCNT2;NRG1;CD47;POU3F2;PTPN2	6.92E-05
GO:0022409	positive regulation of cell-cell adhesion	GCNT2;CD47	2.16E-04
GO:0048522	positive regulation of cellular process	GCNT2;NRG1;CD47;POU3F2	2.68E-04
GO:1901185	negative regulation of ERBB signaling pathway	NRG1; PTPN2	3.63E-04
GO:0051896	regulation of protein kinase B signaling	GCNT2; NRG1	4.91E-03
GO:0048665	neuron fate specification	POU3F2	5.19E-03
GO:0048663	neuron fate commitment	POU3F2	9.06E-03
GO:0030198	extracellular matrix organization	ITGB8;CD47	9.45E-03
GO:0014033	neural crest cell differentiation	NRG1	1.04E-02
GO:0070372	regulation of ERK1 and ERK2 cascade	GCNT2;PTPN2	1.09E-02
GO:0009968	negative regulation of signal transduction	NRG1;PTPN2	1.41E-02
GO:0043161	proteasome-mediated ubiquitin-dependent protein catabolic process	TBL1XR1;UBXN4	1.49E-02
GO:0007169	transmembrane receptor protein tyrosine kinase signaling pathway	NRG1; PTPN2	2.65E-02
GO:0007399	nervous system development	NRG1;POU3F2	3.43E-02

F.Common significant GOs of T2D and CP

GO ID	Pathway	Genes in the pathway	Adjusted P-value
GO:1903050	regulation of proteolysis involved in cellular protein catabolic process	EPHA4;UBE3A	1.64E-04
GO:0046058	cAMP metabolic process	PDE4D;PDE3A	1.78E-04
GO:0019933	cAMP-mediated signaling	PDE4D;PDE3A	1.65E-03
GO:0048013	ephrin receptor signaling pathway	EPHA4;DNM1	1.97E-03
GO:0071363	cellular response to growth factor stimulus	ACAP2;PDE3A	5.47E-03
GO:0048681	negative regulation of axon regeneration	EPHA4	6.38E-03
GO:0070571	negative regulation of neuron projection regeneration	EPHA4	7.18E-03
GO:0099590	neurotransmitter receptor internalization	DNM1	8.77E-03
GO:0048679	regulation of axon regeneration	EPHA4	8.77E-03
GO:0021952	central nervous system projection neuron axonogenesis	EPHA4	8.77E-03
GO:0008045	motor neuron axon guidance	EPHA4	8.77E-03
GO:0106030	neuron projection fasciculation	EPHA4	8.77E-03
GO:0009966	regulation of signal transduction	EPHA4;IGFBP5	1.47E-02
GO:0070372	regulation of ERK1 and ERK2 cascade	EPHA4; P2RY1	1.64E-02
GO:0071880	adenylate cyclase-activating adrenergic receptor signaling pathway	PDE4D	1.67E-02
GO:0071875	adrenergic receptor signaling pathway	PDE4D	1.67E-02
GO:1990090	cellular response to nerve growth factor stimulus	ACAP2	1.82E-02
GO:1901701	cellular response to oxygen-containing compound	IGFBP5;PDE3A	1.99E-02
GO:0009968	negative regulation of signal transduction	EPHA4;IGFBP5	2.11E-02
GO:0043410	positive regulation of MAPK cascade	EPHA4; P2RY1	2.20E-02
GO:0007169	transmembrane receptor protein tyrosine kinase signaling pathway	EPHA4; DNM1	3.93E-02
GO:0010977	negative regulation of neuron projection development	EPHA4	4.08E-02
GO:0016192	vesicle-mediated transport	ACAP2;DNM1	4.18E-02
GO:0001934	positive regulation of protein phosphorylation	EPHA4;P2RY1	4.22E-02

G.Common significant GOs of T2D and CP

GO ID	Pathway	Genes in the pathway	Adjusted P-value
GO:0070229	negative regulation of lymphocyte apoptotic process	PRKCQ; FOXP1	4.32E-04
GO:0099590	neurotransmitter receptor internalization	DNM1; DNM2	5.27E-04
GO:0061025	membrane fusion	RIMS1;DNM1;DNM2	6.95E-04
GO:0043112	receptor metabolic process	ACKR3;DNM1;DNM2	8.54E-04
GO:0051588	regulation of neurotransmitter transport	RIMS1; KCNMB4	8.67E-04
GO:0050804	modulation of chemical synaptic transmission	GRIA2;RIMS1;KCNMB4	2.29E-03
GO:0046928	regulation of neurotransmitter secretion	RIMS1;KCNMB4	3.50E-03
GO:2000146	negative regulation of cell motility	IGFBP5;FBLN1;SRGAP1	3.66E-03
GO:0071320	cellular response to cAMP	IGFBP5;HCN1	4.28E-03
GO:0072384	organelle transport along microtubule	TRAK1;BICD1	4.56E-03
GO:0007009	plasma membrane organization	PACSIN2;SPTBN1	6.06E-03
GO:0048661	positive regulation of smooth muscle cell proliferation	MEF2D;FOXP1	6.38E-03
GO:0090181	regulation of cholesterol metabolic process	SQLE;SP1	7.75E-03

GO:0048660	regulation of smooth muscle cell proliferation	IGFBP5;FOXP1	8.86E-03
GO:0001508	action potential	KCNMB4;CACNA1E	1.30E-02
GO:0007411	axon guidance	FRS2;PRKCQ;SPTBN1	1.38E-02
GO:0072657	protein localization to membrane	PIGR;RFTN1;SPTBN1	1.43E-02
GO:0007517	muscle organ development	MKX;MEF2D	1.59E-02
GO:0007005	mitochondrion organization	TRAK1;DNM1;DNM2	1.60E-02
GO:0010595	positive regulation of endothelial cell migration	SP1;FOXP1	2.11E-02
GO:0010646	regulation of cell communication	GRIA2;CXORF36	2.17E-02
GO:0038127	ERBB signaling pathway	PIGR;NRG1	2.70E-02
GO:0050658	RNA transport	RFTN1;SRSF3	2.70E-02
GO:0007088	regulation of mitotic nuclear division	NPM2;CDC14B	2.95E-02
GO:0010628	positive regulation of gene expression	RIMS1;SP1;TBL1XR1 ITGB8;FLI1;DNM2	3.43E-02
GO:0033365	protein localization to organelle	PACSIN2;BICD1	3.83E-02
GO:0098916	anterograde trans-synaptic signaling	GRIA2;KCNMB4;CACNA1E	4.05E-02
GO:0006406	mRNA export from nucleus	SRSF3;NUP58	4.41E-02
GO:2000145	regulation of cell motility	FBLN1;NRG1	4.71E-02
GO:0014033	neural crest cell differentiation	NRG1	4.92E-02

D. Protein- protein-protein interaction (PPI) analysis

Protein-protein interaction networks (PPINs) are the mathematical representation of the physical contacts of proteins in the cell. Protein-protein interactions (PPIs) are essential to every molecular and biological process in a cell, so PPIs is crucial to understand cell physiology in disease and healthy states [37]. The malfunction of a protein complex causes multiple diseases by the malfunction of a protein complex. Two diseases are potentially related to each other if they share one or more commonly associated protein sub network. Having identified genes involved in pathways and processes common to T2D and the Neurological diseases, we sought evidence for existing sub-networks based on known PPI. Using the enriched common disease genesets, we constructed putative PPI networks using web-based visualization resource STRING [38] by the distinct 159 differentially expressed genes as shown in Fig3. The network is also grouped into 7 clusters using the MCL clustering technique representing NDs to depict the protein belongings. The CDC14B protein belongs to the maximum 3 clusters ALS, ED, and MSD whereas NRG1 protein belongs to the 3 clusters ALS, HD, and MSD which interacts with other proteins from different clusters.FLI1, PACSIN2, ENTPD1, ZBTB7A, DNM1, SGCB, and FUT6 proteins belong to two clusters and interact with proteins in the network. For topological analysis, a simplified PPI network was constructed using Cyto-Hubba plugin [39] to show 10 most significant hub proteins as shown in Fig. 4 which are DNM2, DNM1, MYH14, PACSIN2, TFRC, PDE4D, ENTPD1, PLK4, CDC20B, and CDC14A. This data provides evidence that PPI sub-network exists in our enriched genesets, and confirm the presence of relevant functional pathways. Moreover, thus, these proteins could be the targeted proteins for drug development.

Fig.3. Protein-protein interaction network of the commonly significant Dysregulated genes of the NDs with T2D. Each cluster indicates the gene belongings.

Fig.4. The simplified PPI network of the commonly dysregulated genes between NDs and T2D. The 10 most significant hub proteins are marked as red, orange and yellow.

E. Validating Biomarkers by Gold Benchmark Databases

We presented a combined relation of OMIM, OMIM Expanded and dbGap databases. For cross checking the validity of our study, we collected genes and disease names from OMIM Disease,

OMIM Expanded and dbGap databases using differentially expressed genes of T2D. To find out significant neurological diseases, manual curation is applied considering adjusted p-value below or equal to 0.05. Then, several diseases such as cancer, infectious diseases etc. are removed from this list because they are not concerned in this study. After analyzing them, 5 neurological diseases are found. Then, we construct a GDN using Cytoscape and show gene-disease association of different diseases as shown in Fig. 5. It indicates our analysis of finding significant genes of neurological diseases are also matched with existing records.

Fig.5. Disease network of T2D with several NDs. Red color hexagon-shaped nodes represent our selected five NDs. Violet colored hexagon-shaped nodes represent different categories of NDs. A link is placed between a disease and gene if mutations in that gene lead to the specific diseases.

IV. DISCUSSION

Our analysis fills a significant gap in our knowledge about how T2D may affect AD, PD, ALS, ED, HD, CP, and MSD. We used a simple sequence of steps that employ widely available resources and data and can easily be applied to a range of possible co-morbidities. Based on the combined analysis of transcriptomics, genetics, PPIs, pathways and GO data, our disease network disclosed potentially novel disease relationships that have not been captured by previous individual studies. These may inform future clinical co-morbidity studies. The underlying hypothesis behind this line of research is that once we catalogue all (or a large proportion of) disease-related genes, PPI complex, and signaling pathways, we will be able to predict the susceptibility of individuals to other diseases using molecular biomarkers. Combined with genetic data such analyses will be a key element in the development of truly predictive medicine. Our results show a combination of

molecular and population-level data that provide insights about the novel hypothesis of disease mechanism. Furthermore, it will provide important information about medication overlaps and the probability of developing disease co-morbidity, i.e., where the occurrence of one disease in a patient may increase the susceptibility to or severity of another disease using molecular biomarkers. This observation makes us to understand the correlation between various neurological diseases from the molecular and genetic aspects. This analysis will also be considered as a key element of predictive drugs development.

This work showed significant associations of neurological diseases with the corresponding T2D by substantial pathways. To explore the pathway (and transcript profile) overlaps can indicate disease associations and co-morbid vulnerability. We analyzed publicly available microarray data thus can be applied wherever such data exists. Our approach employed differentiation gene expression analyses, followed by gene enrichment using signaling pathway and Gene Ontology (GO) data. One particular technical point is that with pathway and GO analyses a large number of categories were reduced by manual curation. Besides, flexible, time-consuming and semantic analysis-based approaches are used to facilitate this work and reduce operator bias. In transcript analyses, it is found evidence about the processing of disease of PPI data. So, we can identify different pathways through the inspection of cell proteins and their interactions. This investigation also represents a high potential for understanding the central mechanisms behind the disease or disorder progression. We have also analyzed the differentially expressed genes of T2D with gold benchmark dataset OMIM, OMIM Expanded and dbGaP databases using EnrichR to validate our identified results and depicted as gene-disease associations as shown in Fig. 4. These results corroborate that, the differentially expressed genes of T2D are responsible for the progression of NDs. As a whole, our findings compensate a major gap of about T2D biology. It will also open up an entry point to establish a mechanic link between the T2D and various neurological diseases.

V. CONCLUSIONS

In this study, we have considered Gene Expression Omnibus (GEO) microarray data from type 2 diabetes (T2D), Parkinson's disease (PD), Alzheimer's disease (AD), Amyotrophic Lateral Sclerosis(Lou Gehrig's disease) ALS (LGD), Epilepsy disease (ED),Huntington Disease (HD),Cerebral Palsy(CP) , Multiple Sclerosis disease (MSD) and control datasets to analysis and investigate the genetic effects of T2D on neurological diseases (NDs). We analyzed dysregulated genes, disease relationship networks, dysregulated pathways, gene expression ontologies and protein-protein interactions of T2D and NDs. Our findings showed that T2D have a strong association with NDs.This study demonstrates that T2D shares several common multifactorial degenerative biological process that contributes to neuronal death,which leads to functional impairment. Because of these multifactorial aspects and complexity, our proposed gene

expression analysis platforms have been extensively used to investigate altered pathways and to identify potential biomarkers and drug targets. Although many therapeutic approaches has been tested, no effective cure for these neurological diseases has been identified. Therefore, high-throughput technique like whole genome transcriptomics and microarray technology must be coupled with functional genomics and proteomics in an effort to identify specific and selective biomarkers and viable drug targets which allow the successful discovery of disease modifying therapeutic targets. Therapeutic targets aimed at attenuating the above mentioned altered pathways could possibly ameliorate neurological dysfunction in T2D patient. This kind of study will be useful for making genomic evidence-based recommendations about the accurate disease prediction, identification, and making society aware of the dangerous effect of T2D on the human body.

Acknowledgments

Thanks are due to Dou Hao and those anonymous scholars who offered advice on the improvement of the paper. This work is financially supported by the National Natural Science Foundation of China (Grant No.61571438).Thanks to CAS-TWAS Presidents Fellowship for supporting me(MHR) as a doctoral student (Fellowship No.2016CTF0146).

References

- [1] Libman IM, Becker DJ. Coexistence of type 1 and type 2 diabetes mellitus: "double" diabetes? *Pediatr Diabetes*. 2003;4(2):110–3.
- [2] Ahmed AM, History of diabetes mellitus.*Saudi Med J* 2002 Apr;23(4):373-378
- [3] Diabetes mellitus history-from ancient to modern times. Available at <http://science.jrank.org/pages/2044/Diabetes-Mellitus.html>(accessed on 29th September 2018)
- [4] Patlak M. New weapons to combat an ancient disease: treating diabetes.*FASEB J* 2002 December;16(14):1853.
- [5] Chamnan P, Simmons RK, Forouhi NG, Luben R, Khaw ky, Wareham NJ et al.Incidence of type 2 diabetes using proposed HbA1c diagnostic criteria in the EPIC-Norfolk cohort: Implication for preventive strategies.Available at <http://care.diabetesjournal.org>.(Accesses on 29th September 2018)
- [6] Kalaria.R.N. Diabetes, microvascular pathology, and Alzheimer disease, *Nature reviews neurology*, vol 5, pp. 305-306, 2009.
- [7] [4] Marie-Threse Heemels, Neurodegenerative diseases, *Nature International Journal of Science*, vol. 539, pp. 179,2016.
- [8] Bharadwaj, P., Wijesekara, N., Liyanapathirana, M., Newsholme, P., Ittner, L., Fraser, P., & Verdile, G.(2017).The link between Type 2 diabetes and Neurodegeneration: Roles for Amyloid- β , Amylin, and Tau Proteins.

- [9] Kovacs, G. (2016). Molecular Pathological Classification of Neurodegenerative Diseases: Turning towards Precision Medicine. *International Journal of Molecular Sciences*, 17(2), 189. doi:10.3390/ijms17020189
- [10] Mojtaba Golpich, Elham Amini, Zahurin Mohamed, Raymond Azman Ali, Norlinah Mohamed Ibrahim, Abolhassan Ahmadiani, Mitochondrial Dysfunction and Biogenesis in Neurodegenerative diseases: Pathogenesis and Treatment, *CNS Neuroscience & Therapeutics*, vol. 23, no. 1, pp. 5-22, 2017.
- [11] Neurological Disorders. In Canales, JJ (Ed.), *Adult Neurogenesis in the Hippocampus: Health, Psychopathology, and Brain Disease*, p. 249-275. London, UK: Academic Press / Elsevier, 2016
- [12] Janson, J., Laedtke, T., Parisi, J. E., O'Brien, P., Petersen, R. C., & Butler, P. C. (2004). Increased Risk of Type 2 Diabetes in Alzheimer Disease. *Diabetes*, 53(2), 474-481. doi:10.2337/diabetes.53.2.474
- [13] Hu, G., Jousilahti, P., Bidel, S., Antikainen, R., & Tuomilehto, J. (2007). Type 2 Diabetes and the Risk of Parkinson's disease. *Diabetes Care*, 30(4), 842-847.
- [14] Mariosa, D., Kamel, F., Bellocco, R., Ye, W., & Fang, F. (2015). Association between diabetes and amyotrophic lateral sclerosis in Sweden. *European Journal of Neurology*, 22(11), 1436-1442. doi:10.1111/ene.12632
- [15] Palop, J. J. (2009). Epilepsy and Cognitive Impairments in Alzheimer Disease. *Archives of Neurology*, 66(4), 435. doi:10.1001/archneurol.2009.15
- [16] Karasinska, J. M., & Hayden, M. R. (2011). Cholesterol metabolism in Huntington disease. *Nature Reviews Neurology*, 7(10), 561-572. doi:10.1038/nrneurol.2011.132
- [17] Preetika Chandna, Nikhil Srivastava, Vivek K. Adlakha and Shamsher Singh (2014), "An Overview of Oral Findings in Cerebral Palsy Patients," *JMED Research*, Vol. 2014 (2014), Article ID 384840, DOI: 10.5171/2014.384840
- [18] Withaker JN, Mitchell GW. Clinical features of multiple sclerosis. In: Raine CS, McFarland HF, Tourtellotte WW, eds. *Multiple sclerosis: clinical and pathogenetic basis*. London: Chapman and Hall, 1997; 3-19.
- [19] Sadovnick AD, Ebers GC, Dymment DA, Risch NJ. Evidence for genetic basis of multiple sclerosis. The Canadian Collaborative Study Group. *Lancet* 1996; 347: 1728-30.
- [20] Misu H, Takamura T, Takayama H, Hayashi H et al. A liver-derived secretory protein, selenoprotein P, causes insulin resistance. *Cell Metab* 2010 Nov 3;12(5):483-95. PMID: 21035759
- [21] Blalock EM, Buechel HM, Popovic J, Geddes JW et al. Microarray analyses of laser-captured hippocampus reveal distinct gray and white matter signatures associated with incipient Alzheimer's disease. *J Chem Neuroanat* 2011 Oct;42(2):118-26. PMID: 21756998
- [22] Lewandowski NM, Ju S, Verbitsky M, Ross B et al. Polyamine pathway contributes to the pathogenesis of Parkinson disease. *Proc Natl Acad Sci U S A* 2010 Sep 28;107(39):16970-5. PMID: 20837543

- [23] Dangond F, Hwang D, Camelo S, Pasinelli P et al. Molecular signature of late-stage human ALS revealed by expression profiling of postmortem spinal cord gray matter. *Physiol Genomics* 2004 Jan 15;16(2):229-39. PMID: 14645737
- [24] Carlet M, Janjetovic K, Rainer J, Schmidt S et al. Expression, regulation and function of phosphofructo-kinase/fructose-biphosphatases (PFKFBs) in glucocorticoid-induced apoptosis of acute lymphoblastic leukemia cells. *BMC Cancer* 2010 Nov 23;10:638. PMID: 21092265
- [25] Borovecki F, Lovrecic L, Zhou J, Jeong H et al. Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease. *Proc Natl Acad Sci U S A* 2005 Aug 2; 102(31):11023-8. PMID: 16043692
- [26] Smith LR, Chambers HG, Subramaniam S, Lieber RL. Transcriptional abnormalities of hamstring muscle contractures in children with cerebral palsy. *PLoS One* 2012;7(8):e40686. PMID: 22956992
- [27] Han MH, Lundgren DH, Jaiswal S, Chao M et al. Janus-like opposing roles of CD47 in autoimmune brain inflammation in humans and mice. *J Exp Med* 2012 Jul 2;209(7):1325-34. PMID: 22734047
- [28] M. Kohl, S. Wiese, and B. Warscheid, "Cytoscape: software for visualization and analysis of biological networks," in *Data Mining in Proteomics*. Springer, 2011, pp. 291–303.
- [29] [19] Mohammad Ali Moni and Pietro Lio, Genetic Profiling and Comorbidities of Zika Infection, *The Journal of Infectious Diseases*, vol. 216, pp. 703-712, 2017.
- [30] Moni MA, Li P, comoR: a software for disease comorbidity risk assessment, *J Clin Bioinforma*, vol. 4, no. 1, 2014.
- [31] Moni MA, Li P, How to build personalized multi-omics comorbidity profiles, *Front Cell Dev Biol*, vol. 3, no. 28, 2015.
- [32] M. V. Kuleshov, M. R. Jones, A. D. Rouillard, N. F. Fernandez, Q. Duan, Z. Wang, S. Koplev, S. L. Jenkins, K. M. Jagodnik, A. Lachmann et al. "Enrichr: a comprehensive gene set enrichment analysis web server 2016
- [33] M. Kanehisa, S. Goto, Y. Sato, M. Furumichi, and M. Tanabe. Kegg for integration and interpretation of large-scale molecular data sets. *Nucleic acids research*, 40(D1):D109–D114, 2011
- [34] Mohammad Ali Moni and Pietro Lio, Network-based analysis of comorbidities risk during an infection: SARS and HIV case studies, vol. 15, no. 333, 2014.
- [35] Lv Jin, Xiao-Yu Zuo, Wei-Yang Su, and et al., Pathway-based Analysis Tools for Complex Diseases: A Review, *Genomics, Proteomics & Bioinformatics*, vol. 12, no. 5, pp. 210-220, 2014.
- [36] Bioportal, Gene Regulation Ontology, [Online]. Available: <https://bioportal.bioontology.org/ontologies/GRO>. [Accessed: 8 - October - 2018].

- [37] Network Analysis of Protein Interaction Data: AN Introduction/ Protein-protein Interaction Networks, [Online]. Available: <https://www.ebi.ac.uk/training/online/course/networkanalysis-protein-protein-interaction-data-introduction/>. [Accessed: 08 - October - 2018].
- [38] D. Szklarczyk, A. Franceschini, S. Wyder, K. Forslund, D. Heller, J. Huerta-Cepas, M. Simonovic, A. Roth, A. Santos, K. P. Tsafou, et al. String v10: protein-protein interaction networks, integrated over the tree of life. *Nucleic acids research*, 43(D1): D447–D452, 2014.
- [39] Chen, Shu-Hwa, et al., "cyto-Hubba: A Cytoscape plug-in for hub object analysis in network biology," 20th International Conference on Genome Informatics, 2009.